Literature DB >> 11420412

Impaired interferon gamma-mediated immunity and susceptibility to mycobacterial infection in childhood.

N Remus1, J Reichenbach, C Picard, C Rietschel, P Wood, D Lammas, D S Kumararatne, J L Casanova.   

Abstract

Mendelian susceptibility to poorly virulent mycobacteria such as bacillus Calmette-Guerin (BCG) and environmental nontuberculous mycobacteria is a clinically heterogeneous syndrome. The clinical features of affected children cover a continuous spectrum from disseminated lethal bacillus Calmette-Guerin infection to local recurrent nontuberculous mycobacterial infection. Different types of mutations in four genes (IFNGR1, IFNGR2, IL12B, IL12RB1) have revealed both allelic and nonallelic heterogeneity and result in eight different disorders whose common pathogenic pathway is impaired interferon gamma (IFNgamma) mediated immunity. The severity of the clinical phenotype depends on the genotype. Complete IL-12 p40 and IL-12 receptor beta1 deficiencies and partial IFNgamma receptor 1 (IFNgammaR1) and IFNgammaR2 deficiencies generally lead to curable infections at various ages, and antibiotics supplemented with IFNgamma if required are likely to be effective. Complete IFNgammaR1 and IFNgammaR2 deficiencies predispose to overwhelming infection in early childhood, which may respond to antibiotics but relapse when antibiotics are discontinued. Rapid discrimination between complete IFNgammaR1 and IFNgammaR2 deficiency and other defects, therefore, is an important diagnostic step for planning clinical management.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11420412     DOI: 10.1203/00006450-200107000-00005

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  19 in total

1.  Patient-centred screening for primary immunodeficiency: a multi-stage diagnostic protocol designed for non-immunologists.

Authors:  E de Vries
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

2.  Interferon-gamma response to the treatment of active pulmonary and extra-pulmonary tuberculosis.

Authors:  L Liang; R Shi; X Liu; X Yuan; S Zheng; G Zhang; W Wang; J Wang; K England; L E Via; Y Cai; L C Goldfeder; L E Dodd; C E Barry; R Y Chen
Journal:  Int J Tuberc Lung Dis       Date:  2017-10-01       Impact factor: 2.373

3.  Recurrent Salmonellosis in a Child with Complete IL-12Rβ1 Deficiency.

Authors:  Mohammad Faizan Zahid; Syed Asad Ali; Fyezah Jehan; Abdul Gaffar Billo; Jean-Laurent Casanova; Jacinta Bustamante; Stephanie Boisson-Dupuis; Fatima Mir
Journal:  J immunodefic Disord       Date:  2014-06-04

4.  Mendelian susceptibility to mycobacterial infection should be ruled out in Mycobacterium chelonae empyema.

Authors:  Luis Ignacio González-Granado
Journal:  Ann Thorac Med       Date:  2010-01       Impact factor: 2.219

5.  ISG15 regulates IFN-γ immunity in human mycobacterial disease.

Authors:  Jun-Bao Fan; Dong-Er Zhang
Journal:  Cell Res       Date:  2012-09-11       Impact factor: 25.617

Review 6.  Safety and efficacy of neonatal vaccination.

Authors:  Alicia Demirjian; Ofer Levy
Journal:  Eur J Immunol       Date:  2009-01       Impact factor: 5.532

7.  Intrathoracic nontuberculous mycobacterial infections in otherwise healthy children.

Authors:  Alexandra F Freeman; Kenneth N Olivier; Thomas T Rubio; Glen Bartlett; James W Ochi; Reginald J Claypool; Li Ding; Douglas B Kuhns; Steven M Holland
Journal:  Pediatr Pulmonol       Date:  2009-11

8.  Nonredundant functions of alphabeta and gammadelta T cells in acrolein-induced pulmonary pathology.

Authors:  Michael T Borchers; Scott C Wesselkamper; Bryan L Eppert; Gregory T Motz; Maureen A Sartor; Craig R Tomlinson; Mario Medvedovic; Jay W Tichelaar
Journal:  Toxicol Sci       Date:  2008-05-29       Impact factor: 4.849

Review 9.  Immune deficiencies due to defects in cytokine signaling.

Authors:  John Kelly; Warren J Leonard
Journal:  Curr Allergy Asthma Rep       Date:  2003-09       Impact factor: 4.806

10.  The transcription factor NFATp plays a key role in susceptibility to TB in mice.

Authors:  Laura E Via; Alla V Tsytsykova; Ricardo Rajsbaum; James V Falvo; Anne E Goldfeld
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.